drugset

drugset / Trial / NCT02984644

Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin

NCT02984644 ↗

Phase 3 Completed 30 enrolled The University of Texas Health Science Center at San Antonio

RandomizedParallel-groupSingle-blindTreatment

Summary

To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.

Timeline

Start: 2017-09-06
Primary completion: 2018-11-16
Completion: 2019-11-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dapagliflozin	Small molecule	10 mg	—

Indications